{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036999","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.307622+00:00","generated_at":"2026-05-17T22:08:39.717741+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M","bullets":["Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.","Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.","NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.","DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.","Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036999","json":"https://secwatch.observer/filing/0001628280-25-036999.json","markdown":"https://secwatch.observer/filing/0001628280-25-036999.md","text":"https://secwatch.observer/filing/0001628280-25-036999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/0001628280-25-036999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/cort-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:08:39.717741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}